CD71+红系细胞促进多发性骨髓瘤进展并损害抗菌免疫应答
研究利用与人类疾病高度相似的小鼠多发性骨髓瘤模型,发现多发性骨髓瘤进展伴贫血及表达精氨酸酶2(ARG2)的未成熟CD71+红系细胞(CEC)增多,后者抑制T细胞增殖并损害免疫应答。ARG2缺陷小鼠多发性骨髓瘤进展更慢、生存改善,且荷瘤小鼠对单核细胞增生李斯特菌感染易感性增高,提示ARG2表达CEC在多发性骨髓瘤相关免疫抑制和感染易感性中起关键作用,ARG2为潜在治疗靶点。
要点
- 多发性骨髓瘤进展伴贫血和表达ARG2的未成熟CD71+红系细胞增多。
- 多发性骨髓瘤相关CD71+红系细胞抑制T细胞增殖,损害免疫应答。
- ARG2缺陷小鼠多发性骨髓瘤进展更慢、生存改善,提示ARG2为潜在治疗靶点。
核心结论
- 表达ARG2的CD71+红系细胞在多发性骨髓瘤相关免疫抑制和感染易感性中起关键作用。
- ARG2被指出是增强多发性骨髓瘤患者免疫功能和降低感染风险的潜在治疗靶点。
研究设计与样本
- 研究采用与人类疾病高度相似的小鼠多发性骨髓瘤模型。
主要发现
- 多发性骨髓瘤进展与贫血及未成熟CD71+红系细胞增多相关,后者以ARG2表达升高为特征。
- 多发性骨髓瘤相关CD71+红系细胞抑制T细胞增殖,导致免疫应答受损。
- ARG2缺陷小鼠多发性骨髓瘤进展更慢且生存改善。
- 荷瘤小鼠对单核细胞增生李斯特菌(Listeria monocytogenes)感染易感性更高,与多发性骨髓瘤患者感染风险增加相呼应。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM), one of the most frequent haematological malignancies, significantly increases the risk of bacterial infections due to treatment-related side effects, comorbidities and cancer-induced immune deficiencies. Recently, CD71+ erythroid cells (CECs) have been identified as key immunomodulators in neonates and cancer patients, but their role in MM progression remains unclear. Using a murine MM model, closely resembling human disease, we observed that MM progression is associated with anaemia and an increase in immature CECs, which are characterized by elevated arginase 2 (ARG2) expression. These MM-associated CECs suppress T-cell proliferation, contributing to impaired immune responses. Notably, ARG2 deficiency in mice led to slower MM progression and improved survival. Furthermore, MM-bearing mice exhibited higher susceptibility to Listeria monocytogenes infections, mirroring the increased infection risk in MM patients. Our findings suggest that ARG2-expressing CECs play a critical role in MM-associated immune suppression and infection susceptibility, pointing out ARG2 as a potential therapeutic target to enhance immune function and reduce infection risks in MM patients.
引用
- Czubak K, Grzywa TM, Sidor-Dzitkowska K, et al. CD71+ erythroid cells promote multiple myeloma progression and impair anti-bacterial immune response. Br J Haematol. 2024. PMID: 39567409. doi:10.1111/bjh.19914
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。